X0508 4 2026-01-02 0001607678 Viking Therapeutics, Inc. VKTX 0001838112 Mancini Marianna C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 false true false false Chief Operating Officer false Common Stock, par value $0.00001 per share 2026-01-02 4 A false 41000 0 A 434802 D Common Stock, par value $0.00001 per share 2026-01-02 4 A false 32049 0 A 466851 D Common Stock, par value $0.00001 per share 2026-01-05 4 S false 31961 32.2928 D 434890 D Common Stock, par value $0.00001 per share 2026-01-05 4 S false 13600 33.3732 D 421290 D Common Stock, par value $0.00001 per share 2026-01-05 4 S false 10500 34.2193 D 410790 D Common Stock, par value $0.00001 per share 2026-01-05 4 S false 1600 35.0731 D 409190 D Stock Option (Right to Buy) 35.42 2026-01-02 4 A false 91000 0 A 2036-01-02 Common Stock 91000 91000 D Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Includes 11,111 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 108 shares acquired on May 20, 2025 and 116 shares acquired on November 20, 2025 both pursuant to the Issuer's 2024 Employee Stock Purchase Plan. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026, upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of the shares subject to the option will vest on each anniversary of the grant date. /s/ Michael Morneau, as Attorney-in-Fact 2026-01-05